Fig. 3

Map9-YFP RNA can partially rescue the phenotypes of MOex5 morphants. (A) Embryos were injected at the 1-cell stage with 1 pmol MOex5, 200 pg map9-YFP RNA or map9ΔCter-YFP RNA, or co-injected with MOex5 and either RNA. Map9-YFP- and map9ΔCter-YFP-injected embryos developed normally up to mid-epiboly and later stages (green). Forty % of MOex5 morphants showed defects at mid-epiboly (red), 20% were blocked at the sphere stage (blue), and all of them died at 9-10 hpf. Following co-injection of MOex5 and map9-YFP RNA, about 80% of embryos developed normally up to mid-epiboly but died before 24 hpf, whereas co-injection with map9ΔCter-YFP did not rescue the morphant phenotype (n = 64 for map9ΔCter-YFP-injected embryos; n = 54 for embryos co-injected with MOex5 and map9ΔCter-YFP RNA). (B) Representative images of embryos injected with map9-YFP RNA (at mid-epiboly, n = 102), with MOex5 (showing developmental delay and defects before mid-epiboly, n = 85), or with both MOex5 and map9-YFP RNA (showing partial rescue of the phenotype at mid-epiboly, n = 153). Scale bars, 200 µm.